Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0FZNCB)
| ADC Name |
HLX48
|
|||||
|---|---|---|---|---|---|---|
| Organization |
Shanghai Henlius Biotech (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Anti-EGFR/c-Met bsAb
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Payload Target |
Undisclosed
|
|||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC